| Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... The Lancet 393 (10185), 2051-2058, 2019 | 1640 | 2019 |
| Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional … DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ... Journal of Clinical Oncology 37 (18), 1558-1565, 2019 | 1054 | 2019 |
| Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic … DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ... The lancet oncology 17 (12), 1672-1682, 2016 | 1031 | 2016 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial DA Palma, R Olson, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy, ... Journal of Clinical Oncology 38 (25), 2830-2838, 2020 | 895 | 2020 |
| Volumetric modulated arc therapy for delivery of prostate radiotherapy: comparison with intensity-modulated radiotherapy and three-dimensional conformal radiotherapy D Palma, E Vollans, K James, S Nakano, V Moiseenko, R Shaffer, ... International Journal of Radiation Oncology* Biology* Physics 72 (4), 996-1001, 2008 | 714 | 2008 |
| Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis DA Palma, S Senan, K Tsujino, RB Barriger, R Rengan, M Moreno, ... International Journal of Radiation Oncology* Biology* Physics 85 (2), 444-450, 2013 | 711 | 2013 |
| Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non–small-cell lung cancer: a population-based time-trend analysis D Palma, O Visser, FJ Lagerwaard, J Belderbos, BJ Slotman, S Senan Journal of clinical oncology 28 (35), 5153-5159, 2010 | 537 | 2010 |
| An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non–small-cell lung cancer AB Ashworth, S Senan, DA Palma, M Riquet, YC Ahn, U Ricardi, ... Clinical lung cancer 15 (5), 346-355, 2014 | 456 | 2014 |
| Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document Y Lievens, M Guckenberger, D Gomez, M Hoyer, P Iyengar, I Kindts, ... Radiotherapy and Oncology 148, 157-166, 2020 | 442 | 2020 |
| Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial AC Nichols, J Theurer, E Prisman, N Read, E Berthelet, E Tran, K Fung, ... The Lancet Oncology 20 (10), 1349-1359, 2019 | 412 | 2019 |
| Stage I–II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a … NE Verstegen, JWA Oosterhuis, DA Palma, G Rodrigues, FJ Lagerwaard, ... Annals of oncology 24 (6), 1543-1548, 2013 | 326 | 2013 |
| Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature A Ashworth, G Rodrigues, G Boldt, D Palma Lung cancer 82 (2), 197-203, 2013 | 312 | 2013 |
| The oligometastatic state—separating truth from wishful thinking DA Palma, JK Salama, SS Lo, S Senan, T Treasure, R Govindan, ... Nature reviews Clinical oncology 11 (9), 549-557, 2014 | 299 | 2014 |
| Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement M Guckenberger, C Belka, A Bezjak, J Bradley, ME Daly, D DeRuysscher, ... Radiotherapy and Oncology 146, 223-229, 2020 | 252 | 2020 |
| New developments in arc radiation therapy: a review DA Palma, WFAR Verbakel, K Otto, S Senan Cancer treatment reviews 36 (5), 393-399, 2010 | 247 | 2010 |
| Radiographic changes after lung stereotactic ablative radiotherapy (SABR)–can we distinguish recurrence from fibrosis? A systematic review of the literature K Huang, M Dahele, S Senan, M Guckenberger, GB Rodrigues, A Ward, ... Radiotherapy and Oncology 102 (3), 335-342, 2012 | 243 | 2012 |
| Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review D Palma, F Lagerwaard, G Rodrigues, C Haasbeek, S Senan International Journal of Radiation Oncology* Biology* Physics 82 (3), 1149-1156, 2012 | 227 | 2012 |
| Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement DJ Thomson, D Palma, M Guckenberger, P Balermpas, JJ Beitler, ... International Journal of Radiation Oncology* Biology* Physics 107 (4), 618-627, 2020 | 226 | 2020 |
| Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial DA Palma, R Olson, S Harrow, RJM Correa, F Schneiders, CJA Haasbeek, ... BMC cancer 19, 1-15, 2019 | 200 | 2019 |
| Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis DA Palma, S Senan, C Oberije, J Belderbos, NR De Dios, JD Bradley, ... International Journal of Radiation Oncology* Biology* Physics 87 (4), 690-696, 2013 | 191 | 2013 |
